Shares in Orexo AB fell more than 10 percent Tuesday on news that the Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc., was terminating an alliance to develop drugs targeting pathways involved in arachidonic acid metabolism.
Cancer Research Technology (CRT; London), the technology commercialization arm of Cancer Research UK, has spun out a new start-up, Acublate, to take forward a next-generation high intensity focused ultrasound (HIFU) surgery device that could offer safety and performance advantages over existing HIFU systems for treating solid tumors.
Prosensa Therapeutics BV raised €23 million (US$29.9 million) in a Series C round to enable it to move two new exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and to take forward preclinical programs in two other rare disease indications.
Santhera Pharmaceuticals AG is looking for a new partner for its Parkinson's disease drug fipamezole after Ipsen SA returned its rights to the drug, which covered territories outside of North America and Japan.
Santhera Pharmaceuticals AG is looking for a new partner for its Parkinson's disease drug fipamezole after Ipsen SA returned its rights to the drug, which covered territories outside of North America and Japan.
Shares in 4SC AG surged more than 38 percent last week on news that its histone deacetylase (HDAC) inhibitor resminostat hit the primary endpoint of a Phase II trial in advanced hepatocellular carcinoma (HCC).
Shares in 4SC AG surged more than 38 percent Thursday on news that its histone deacetylase (HDAC) inhibitor resminostat hit the primary endpoint of a Phase II trial in advanced hepatocellular carcinoma (HCC).
Evotec AG entered its second scientific discovery collaboration with Harvard University inside a year. The company is teaming up with Harvard scientists Andy McMahon and Ben Humphreys on an initiative called CureNephron to identify novel targets – and drugs acting on them – that have disease-modifying potential in a range of kidney indications.
Quality management problems at its contract manufacturer, Ben Venue Laboratories Inc., have forced Clavis Pharma ASA to slow recruitment in a Phase III trial of elacytarabine in late-stage acute myeloid leukemia (AML) and will result in a delay of one quarter in the reporting of its results.
